Gary Walsh, PhD

Associate Professor in the Industrial Biochemistry Program at the University of Limerick. He is also a member of BioPharm International's Editorial Advisory Board.

Ten biopharmaceuticals gained marketing authorization in the US or EU in 2008, although only four were new approvals.

The year 2007 witnessed the approval of fifteen biopharmaceuticals in the United States and European Union.

The book is a useful, comprehensive, and truly an excellent reference source of biopharmaceutical information.

An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.

There were notable approvals in nonparenteral delivery systems and biosimiliars in 2006.

In 2005, 10 biopharma- ceuticals gained marketing approval in the US or Europe, although only five of them were genuinely new molecular entities.

Cancer remains the primary indication (three products), again mirroring recent approval trends.

As of late 2004, 26 modern antibody-based therapeutic agents have been approved in the European Union and the US. Some 500 such products are currently in development, ensuring that the number of approved antibody-based products will increase substantially over the coming years.